Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminoglycoside vs Cephalosporin Alone in Open Lower Extremity Fractures
NCT05267977Phase 3Withdrawn
- Sponsor
- Methodist Health System
- Start
- Aug 2016
- Primary completion
- May 2022
01
Overview
Phase 3 trial in lower extremity fracture (2 arms), sponsored by Methodist Health System. Primary endpoint: Aminoglycoside Usage at 24 hours. Planned start Aug 2016; status: withdrawn.
02
Conditions
lower extremity fracture
Beyond the preview
Go deeper on NCT05267977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05267977.